To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:612 ISSN#:2564-2537
ACE Report #5098
Ace Report Cover Tumour

MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

How to Cite

OrthoEvidence. MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients. ACE Report. 2013;2(7):612. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566

Contributing Authors: AJ Chou ES Kleinerman MD Krailo Z Chen DL Betcher JH Healey Conrad EU ML Nieder MA Weiner RJ Wells RB Womer PA Meyers Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was eff...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.